



For Immediate Release

EraGen Biosciences Announces Greg R. Johnson, Managing Director, Prolog Ventures, Dr. Tracy Marshbanks, Vice President, First Analysis and Bruce D. Neviasher, General Partner, Continuum Investment, LP, Join Board of Directors

Expanded BOD Will Help Company to Grow Molecular Diagnostics Business
01/30/2006

EraGen Biosciences Inc., a venture-backed biotechnology company focused on automating molecular diagnostics, today announced they have expanded their board of directors to include Greg Johnson, Managing Director, Prolog Ventures, Tracy Marshbanks, Vice President, First Analysis and Bruce Neviasher, General Partner, Continuum Investment, LP.

In addition to Johnson, Marshbanks and Neviasher, the Company's Board of Directors include: Markus Goebel, M.D., Managing Director, Novartis BioVenture Fund, Irene Hrusovsky, M.D., President, CEO and Chairman, EraGen Biosciences and David O'Bryan, Ph.D., Managing Director, Hibernia Consulting Partners.

"We are very pleased by the support of our new investors," said Irene Hrusovsky, M.D., President and CEO of EraGen Biosciences. "2006 will be a pivotal year for EraGen and I have full confidence that our new Board will provide the leadership needed to help guide us to rapid commercialization of innovative diagnostics products using our expanded genetic alphabet technology."

About Greg Johnson

Gregory R. Johnson is a founder and managing director of Prolog Ventures. Greg brings to the firm over two decades of venture capital experience as a manager of venture capital funds and corporate venture capital investment programs. He came to Prolog Ventures following 14 years as a general partner at Gateway Associates, a St. Louis-based venture capital company with more than \$180 million in total funds under management. His activities at Gateway focused on early-stage investments in biotechnology, medical devices and advanced materials. Previously, he was Vice President of Monsanto Venture Capital and Monsanto's Director of New Ventures and Technology. He oversaw Monsanto's \$80 million portfolio of corporate venture capital investments, helped create its international network of funds and worked on commercialization of technology developed at Washington University School of Medicine and Oxford University. Greg holds a doctoral degree in physics from the University of Rochester and a bachelor's degree from MIT.

About Dr. Tracy Marshbanks

Tracy Marshbanks is a Vice President at First Analysis, specializing in research and investment within selected areas of life science and advanced materials sectors. Prior to joining First Analysis in 1999, he worked in the Refining Marketing unit at Amoco Corp. with responsibility for the capital plan for retail stores including placement, acquisitions and divestitures. Earlier, he worked in refining capital planning and as a research engineer at Amoco. He earned a Ph.D. in chemical engineering from Purdue University, an M.B.A. from the University of Chicago and a bachelor's degree in chemical engineering from Colorado State University.

About Bruce D. Neviaser

Bruce Neviaser is the General Partner of Continuum Investment, LP, an angel investment firm, and is Chairman of the Board and co-founder of Great Wolf Resorts, Inc., which recently completed a successful IPO. Mr. Neviaser has over 25 years of experience in hospitality and commercial real estate management, development and acquisition. He serves as a managing partner in a variety of commercial real estate ventures in the United States, including resorts, hotels, shopping centers and land development projects. Mr. Neviaser studied marketing and real estate at the University of Wisconsin, has been a licensed Wisconsin Real Estate Broker and holds a Certified Commercial Investment Member (CCIM) designation from the Realtors National Marketing Institute. He was recently appointed to the Advisory Board of the Weinert Center for Entrepreneurship at the UW-Madison School of Business, is on the Dean's Advisory Board of the University of Wisconsin Grainger School of Business and is on the Business Advisory Board of Phenomenelle Angels Fund I, LP.

About EraGen Biosciences

Based in Madison, Wisconsin, EraGen Biosciences is driving innovative molecular diagnostics to market faster. The company develops and commercializes high performance automated molecular diagnostics products to serve the growing markets for personalized medicine and rapid response needs for homeland security. www.eragen.com

For additional information contact:
Regina Reynolds
Director Corporate Communications
EraGen Biosciences, Inc.
608-662-9000 ext. 306
rreynolds@eragen.com

PR0602